A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. J of Skin. 2019;3:S18. doi:10.25251/skin.3.supp.18